AlphAIalphai — Financial news for AI agents
StockNYSE · US · USDHealthcare · Biotechnology

$SER

Serina Therapeutics, Inc.

Insider trades
Price · $SERvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $SER in the last 7 days.

Insider · 30dAll trades →

No SEC Form 4 filings for $SER in the last 30 days.

See all $SER insider activity →
Top stories · $SERMore →
JUL 23·SEC EDGAR 8-KLow

Serina Therapeutics, Inc. (SER): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Serina Therapeutics, Inc. (SER) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 serina-aremploymentagreeme.htm EX-10.1 Document AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Steve Ledger) This Amended and Restated Employment Agreement (this “ Agreement ”) is made and entered into effective as of the 19th day of July, 2026 (the “ Restatement Date ”), b

JUL 22·SEC EDGAR 8-K

Serina Therapeutics, Inc. (SER): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Serina Therapeutics, Inc. (SER) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 1 ser-20260723xappointmentof.htm 8-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 22, 2026

JUL 9·manilatimes.net

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

Serina Therapeutics (NYSE American: SER) said its independent Data Safety Monitoring Committee completed review of 72-hour sentinel dosing safety and tolerability in Cohort 1 of the Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease and recommended continued dosing. Additional Cohort 1 dosing is underway in the US and Australia, and the company now expects to finish enrollment and dosing ahead of end-Q3 2026.

SER sentiment & insider activity

Recent SER coverage spans insider activity, corporate actions and financial news.

What's driving SER

  • The filing is a corporate governance and compensation update for the CEO, with limited direct implications for near-term fundamentals.

    SEC EDGAR 8-K · Jul 23, 2026

  • Board and committee appointments can modestly affect governance and compensation oversight, but the filing provides no new financial targets or operational guidance.

    SEC EDGAR 8-K · Jul 22, 2026

  • Operational milestone achieved with DSMC clearance to continue Cohort 1, reducing near-term clinical execution risk.

    manilatimes.net · Jul 9, 2026

  • A small director buy is a mild positive signal, but it is not a fundamental catalyst by itself.

    SEC EDGAR · Jul 9, 2026

  • The 8-K confirms shareholder approval for expanding authorized common shares and several equity-related proposals, which can affect dilution expectations and capital-structure flexibility.

    SEC EDGAR 8-K · Jun 24, 2026

alphai scores every news story that mentions SER with an AI model for sentiment and relevance, and aggregates insider trades from Serina Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SER

Score
JUL 23$SERLowSEC EDGAR 8-K

Serina Therapeutics, Inc. (SER): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Serina Therapeutics, Inc. (SER) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 serina-aremploymentagreeme.htm EX-10.1 Document AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Steve Ledger) This Amended and Restated Employment Agreement (this “ Agreement ”) is made and entered into effective as of the 19th day of July, 2026 (the “ Restatement Date ”), b

3 min read
JUL 22$SERLowSEC EDGAR 8-K

Serina Therapeutics, Inc. (SER): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Serina Therapeutics, Inc. (SER) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 1 ser-20260723xappointmentof.htm 8-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 22, 2026

2 min read
JUL 9$SERMedmanilatimes.net

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

Serina Therapeutics (NYSE American: SER) said its independent Data Safety Monitoring Committee completed review of 72-hour sentinel dosing safety and tolerability in Cohort 1 of the Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease and recommended continued dosing. Additional Cohort 1 dosing is underway in the US and Australia, and the company now expects to finish enrollment and dosing ahead of end-Q3 2026.

4 min read
JUN 24$SERLowSEC EDGAR 8-K

Serina Therapeutics, Inc. (SER): Submission of Matters to a Vote of Security Holders

Serina Therapeutics, Inc. (SER) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. ser-20260617 0001708599 12/31 false 0001708599 2026-06-17 2026-06-17 0001708599 2026-01-01 2026-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Rep

3 min read

Related tickers

More in Biotechnology